☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-35050

ENDOCYTE, INC.

(Exact name of Registrant as specified in its charter)

Delaware

35-1969-140

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification Number)

3000 Kent Avenue, Suite A1-100

West Lafayette, IN 47906

(Address of Registrant’s principal executive offices)

Registrant’s telephone number, including area code: (765) 463-7175

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ◻

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ◻

Accelerated filer ☑

Non-accelerated filer ◻
(Do not check if a smaller reporting company)

Smaller reporting company ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ◻ No ☑

Number of shares of the registrant’s Common Stock, $0.001 par value, outstanding on October 31, 2016: 42,268,069

PART I. FINANCIAL INFORMATION

Item 1.
Financial Statements

ENDOCYTE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

December 31,

September 30,

2015

2016

Assets

(unaudited)

Current assets:

Cash and cash equivalents

$

15,431,622

$

34,732,782

Short-term investments

158,168,832

111,983,789

Receivables

8,678

20,000

Prepaid expenses

772,579

1,492,376

Other assets

493,863

311,607

Total current assets

174,875,574

148,540,554

Property and equipment, net

3,398,398

3,396,163

Other noncurrent assets

111,605

49,428

Total assets

$

178,385,577

$

151,986,145

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

1,262,565

$

1,516,856

Accrued wages and benefits

3,272,237

1,701,378

Accrued clinical trial expenses

804,066

902,294

Accrued expenses and other liabilities

850,125

430,668

Total current liabilities

6,188,993

4,551,196

Other liabilities, net of current portion

18,503

7,178

Deferred revenue, net of current portion

831,944

794,444

Total liabilities

7,039,440

5,352,818

Stockholders’ equity:

Common stock: $0.001 par value, 100,000,000 shares authorized; 42,034,733 and 42,268,069 shares issued and outstanding at December 31, 2015 and September 30, 2016

Weighted-average number of common shares used in net loss per share calculation – basic and diluted

41,974,518

42,263,311

41,924,252

42,184,182

See accompanying notes.

3

ENDOCYTE, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

(unaudited)

Accumulated

Additional

Other

Common Stock

Paid-In

Comprehensive

Retained

Shares

Amount

Capital

Income (Loss)

Deficit

Total

Balances December 31, 2015

42,034,733

$

42,035

$

381,118,489

$

(79,399)

$

(209,734,988)

$

171,346,137

Exercise of stock options

66,888

66

129,240

—

—

129,306

Stock-based compensation

121,812

122

7,731,594

—

—

7,731,716

Employee stock purchase plan

44,636

45

137,880

—

—

137,925

Net loss

—

—

—

—

(32,822,796)

(32,822,796)

Unrealized gain on securities

—

—

—

111,039

—

111,039

Balances September 30, 2016

42,268,069

$

42,268

$

389,117,203

$

31,640

$

(242,557,784)

$

146,633,327

See accompanying notes.

4

ENDOCYTE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months Ended September 30,

2015

2016

(unaudited)

Operating activities

Net loss

$

(31,475,655)

$

(32,822,796)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

666,174

679,675

Stock-based compensation

5,221,217

7,889,999

Loss on disposal of property and equipment

7,487

—

Accretion of bond premium

1,027,922

331,881

Change in operating assets and liabilities:

Receivables

827,022

170,934

Prepaid expenses and other assets

(448,548)

(490,175)

Accounts payable

(421,206)

104,079

Accrued wages, benefits and other liabilities

(1,233,116)

(1,933,414)

Deferred revenue

(37,500)

(37,500)

Net cash used in operating activities

(25,866,203)

(26,107,317)

Investing activities

Purchases of property and equipment

(255,623)

(664,673)

Purchases of investments

(51,747,015)

(114,900,851)

Proceeds from sale and maturities of investments

62,899,199

160,865,053

Net cash provided by investing activities

10,896,561

45,299,529

Financing activities

Stock repurchase

(57,273)

(158,283)

Proceeds from the exercise of stock options

339,846

129,306

Proceeds from stock purchases under employee stock purchase plan

169,952

137,925

Net cash provided by financing activities

452,525

108,948

Effect of exchange rate

(1,158)

—

Net increase (decrease) in cash and cash equivalents

(14,518,275)

19,301,160

Cash and cash equivalents at beginning of period

45,533,443

15,431,622

Cash and cash equivalents at end of period

$

31,015,168

$

34,732,782

See accompanying notes.

5

ENDOCYTE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Organization

Endocyte, Inc. (the “Company”) is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The Company uses its proprietary technology to create novel small molecule drug conjugates (“SMDCs”), and companion imaging agents. The SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with a highly active drug at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore most likely to benefit from treatment.

The Company had two wholly-owned subsidiaries, Endocyte Europe B.V. and Endocyte Europe GmbH, which were formed to assist with the administration of applications with the European Commission (“EC”) and commercial pre-launch activities in Europe. The applications were withdrawn in May 2014 and the commercial pre-launch activities in Europe ceased. The Company dissolved Endocyte Europe GmbH in the fourth quarter of 2015 and dissolved Endocyte Europe B.V. in the first quarter of 2016.

2. Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated as of December 31, 2015. The condensed financial statements for the three and nine months ended September 30, 2016 include only the accounts of Endocyte, Inc. as the Company dissolved Endocyte Europe GmbH and Endocyte Europe B.V. in the fourth quarter of 2015 and the first quarter of 2016, respectively. There were no intercompany transactions in the nine months ended September 30, 2016 and no intercompany balances as of September 30, 2016. The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2016 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission.

Segment Information

Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company had performed clinical trials globally and established a subsidiary in The Netherlands to assist in the administration of filing applications in Europe and a subsidiary in Switzerland for commercial pre-launch activities in Europe. The applications filed in Europe were withdrawn in May 2014 and the pre-launch activities in Europe ceased. The Company dissolved Endocyte Europe GmbH in the fourth quarter of 2015 and dissolved Endocyte Europe B.V. in the first quarter of 2016. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment.

6

Use of Estimates

The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts may differ from those estimates.

Cash and Cash Equivalents

The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.

Investments

Investments consist primarily of investments in U.S. Treasuries, U.S. government agency obligations and corporate securities, which could also include commercial paper, that are maintained by an investment manager. U.S. government agency investments relate to investments in Fannie Mae, Freddie Mac and Federal Home Loan Bank. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-
sale
securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320,
Investments — Debt and Equity Securities
(“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expensed over the term of the security.

Revenue Recognition

The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605,
Revenue Recognition
(“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25,
Multiple-Element Arrangements
(“ASC 605-25”). Under ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables.

Upfront payments for licensing the Company’s intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If at the inception of an arrangement the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue on the balance sheet and are recognized in a manner consistent with the final deliverable. Subsequent to the inception of an arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered.

In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative

7

catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred. In the event of an early termination of a collaboration agreement, any deferred revenue is recognized in the period in which all obligations of the Company under the agreement have been fulfilled.

Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e., not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone. Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company’s products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and a collaborator may share profit, the revenue would be recorded in the period earned.

The Company often is required to make estimates regarding drug development and commercialization timelines for compounds being developed pursuant to a collaboration agreement. Because the drug development process is lengthy and the Company’s collaboration agreements typically cover activities over several years, this approach often results in the deferral of significant amounts of revenue into future periods. In addition, because of the many risks and uncertainties associated with the development of drug candidates, the Company’s estimates regarding the period of performance may change in the future. Any change in the Company’s estimates or a termination of the arrangement could result in substantial changes to the period over which the revenues are recognized.

Research and Development Expenses

Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging agents and include salaries, supplies, depreciation, and expenses for clinical trials. The Company records accruals for
clinical
trial expenses based on the estimated amount of work completed.
The
Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations. In the event that a clinical trial is terminated early, the Company records, in the period of termination, an accrual for the estimated remaining costs to complete the trial.

Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20,
Research and Development Arrangements
. Upfront payments made in connection with
business
development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development expenses and are expensed over the service
period
based upon the level of services provided. As of September 30, 2016, the Company had approximately $0.6 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets.

Stock-Based Compensation

The Company accounts for its stock-based compensation pursuant to ASC Topic 718,
Compensation — Stock Compensation
(“ASC 718”), which requires the recognition of the fair value of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant, service-based restricted stock units (“RSUs”), shares available for purchase under the Company’s 2010 Employee Stock Purchase Plan (“ESPP”), and previously included performance-based RSUs (“PRSUs”). For PRSUs issued by the Company, stock-based compensation expense would

8

have been recognized if the Company had determined that it was probable that the performance conditions would be achieved. All PRSUs expired in the nine months ended September 30, 2016. For RSUs issued by the Company, stock-based compensation expense is recognized ratably over the service period. The Company recognizes compensation cost based on the grant-date fair value estimated in accordance with the provisions of ASC 718.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants, PRSUs, RSUs and shares to be purchased under the ESPP are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

Common stock equivalents

As of September 30, 2015 and 2016, the following number of potential common stock equivalents were outstanding:

As of September 30,

2015

2016

Outstanding common stock options

5,693,156

6,544,738

Outstanding warrants

34,647

34,647

Outstanding PRSUs

216,008

—

Outstanding RSUs

352,949

414,018

Shares to be purchased under the ESPP

23,352

34,853

Total

6,320,112

7,028,256

These common stock equivalents were excluded from the determination of diluted net loss per share due to their anti-dilutive effect on earnings.

3. New Accounting Pronouncements

Recently Issued Accounting Standards

In March 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-09,
Improvements to Employee Share-Based Payment Accounting
, an update to ASC Topic 718,
Stock Compensation
. This guidance involves improving several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and the forfeiture rate calculation. This update is effective for the Company for interim and annual reporting periods beginning January 1, 2017 unless it elects early adoption. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02,
Leases
, an update to ASC Topic 842,
Leases
. This guidance requires lessees to recognize leases as assets and liabilities on their balance sheets but recognize expenses on their income statements in a manner similar to the current accounting guidance. For lessors, the guidance also modifies the classification criteria and the accounting for sales-type and direct finance leases. This update is effective for the Company for interim and annual reporting periods beginning January 1, 2019 unless it elects early adoption. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15 (Subtopic 205-40),
Presentation of Financial Statements — Going Concern
, which requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and provide related footnote disclosures. This guidance is effective for the Company for interim and annual reporting periods beginning on or after December 15, 2016. Early adoption is permitted for financial statements

9

that have not been previously issued. The standard allows for either a full retrospective or modified retrospective transition method. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09,
Revenue from Contracts with Customers
(Topic 606), to clarify the principles used to recognize revenue for all entities. Under ASU 2014-09, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In order to do so, an entity would follow the five-step process for in-scope transactions: 1) identify the contract with a customer, 2) identify the separate performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the separate performance obligations in the contract, and 5) recognize revenue when (or as) the entity satisfies a performance obligation. In August 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 by one year. Therefore, ASU 2014-09 will become effective for the Company for interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted, but not any earlier than the original effective date of December 15, 2016. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. In April 2016, the FASB issued ASU 2016-10, an update to Topic 606, which clarifies how entities should identify performance obligations and evaluate licensing. In May 2016, the FASB issued ASU 2016-12, an update to Topic 606, which clarifies guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The Company is currently evaluating the impact, if any, the adoption of this guidance will have on its consolidated financial statements.

4. Other Comprehensive Income (Loss)

The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for the three months ended September 30, 2015 and 2016:

Foreign

Accumulated

Currency

Unrealized Net

Other

Translation

Gains

Comprehensive

Gains (Losses)

on Securities

Gains (Losses)

Balance at June 30, 2015

$

(51,873)

$

23,732

$

(28,141)

Unrealized gain

123

51,419

51,542

Net amount reclassified to net loss

—

—

—

Other comprehensive income

123

51,419

51,542

Balance at September 30, 2015

$

(51,750)

$

75,151

$

23,401

Foreign

Accumulated

Currency

Unrealized Net

Other

Translation

Gains (Losses)

Comprehensive

Gains (Losses)

on Securities

Gains (Losses)

Balance at June 30, 2016

$

—

$

96,246

$

96,246

Unrealized loss

—

(65,901)

(65,901)

Net amount reclassified to net loss

—

1,295

1,295

Other comprehensive loss

—

(64,606)

(64,606)

Balance at September 30, 2016

$

—

$

31,640

$

31,640

10

The following tables summarize the accumulated balances related to each component of other comprehensive income (loss) for the nine months ended September 30, 2015 and 2016:

Foreign

Accumulated

Currency

Unrealized Net

Other

Translation

Gains (Losses)

Comprehensive

Losses

on Securities

Gains (Losses)

Balance at December 31, 2014

$

(50,592)

$

(93,336)

$

(143,928)

Unrealized gain (loss)

(1,158)

173,391

172,233

Net amount reclassified to net loss

—

(4,904)

(4,904)

Other comprehensive income (loss)

(1,158)

168,487

167,329

Balance at September 30, 2015

$

(51,750)

$

75,151

$

23,401

Foreign

Accumulated

Currency

Unrealized Net

Other

Translation

Gains (Losses)

Comprehensive

Gains (Losses)

on Securities

Gains (Losses)

Balance at December 31, 2015

$

—

$

(79,399)

$

(79,399)

Unrealized gain

—

109,744

109,744

Net amount reclassified to net loss

—

1,295

1,295

Other comprehensive income

—

111,039

111,039

Balance at September 30, 2016

$

—

$

31,640

$

31,640

The assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows, which results in translation adjustments being made in stockholders’ equity rather than to net loss.

5. Investments

The Company applies the fair value measurement and disclosure provisions of ASC Topic 820,
Fair Value Measurements and Disclosures
(“ASC 820”). ASC 820, which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Investments consist primarily of investments with original maturities greater than three months, but no longer than 24 months when purchased.

ASC 820 establishes a three-level valuation hierarchy for fair value measurements. These valuation techniques are based upon the transparency of inputs (observable and unobservable) to the valuation of an asset or liability as of the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1
— Valuation is based on quoted prices for identical assets or liabilities in active markets.

Level 2
— Valuation is based on quoted prices for similar assets or liabilities in active markets, or other inputs that are observable for the asset or liability, either directly or indirectly, for the full term of the financial instrument.

Level 3
— Valuation is based upon other unobservable inputs that are significant to the fair value measurement.

The fair value of the Company’s fixed income securities is based on a market approach using quoted market values.

11

The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2015:

Fair Value

Description

Cost

Level 1

Level 2

(Carrying Value)

Cash

Cash

$

5,154,191

$

5,154,191

$

—

$

5,154,191

Cash equivalents

FDIC insured deposits and money market funds

10,277,431

10,277,431

—

10,277,431

Cash and cash equivalents

$

15,431,622

$

15,431,622

$

—

$

15,431,622

Short-term investments (due within 1 year)

U.S. government treasury obligations

$

73,593,081

$

73,560,085

$

—

$

73,560,085

U.S. government agency obligations

55,702,099

55,670,043

—

55,670,043

Corporate obligations

28,953,051

—

28,938,704

28,938,704

Total short-term investments

$

158,248,231

$

129,230,128

$

28,938,704

$

158,168,832

The following table summarizes the fair value of cash and cash equivalents and investments as of September 30, 2016:

Fair Value

Description

Cost

Level 1

Level 2

(Carrying Value)

Cash

Cash

$

7,441,394

$

7,441,394

$

—

$

7,441,394

Cash equivalents

FDIC insured deposits and money market funds

27,291,388

27,291,388

—

27,291,388

Cash and cash equivalents

$

34,732,782

$

34,732,782

$

—

$

34,732,782

Short-term investments (due within 1 year)

U.S. government treasury obligations

$

79,555,312

$

79,590,040

$

—

$

79,590,040

U.S. government agency obligations

8,026,091

8,027,400

—

8,027,400

Corporate obligations

24,370,746

—

24,366,349

24,366,349

Total short-term investments

$

111,952,149

$

87,617,440

$

24,366,349

$

111,983,789

All securities held at December 31, 2015 and September 30, 2016, were classified as available-for-sale as defined by ASC 320.

Total unrealized gross gains were $5,690 and $44,544 as of December 31, 2015 and September 30, 2016, respectively. Total unrealized gross losses were $85,089 and $12,904 as of December 31, 2015 and September 30, 2016, respectively. The Company does not consider any of the unrealized losses to be other-than-temporary impairments because the Company has the intent and ability to hold investments until they recover in value. Total realized gross gains were $1,667 for the nine months ended September 30, 2015. There were no total realized gross gains for the nine months ended September 30, 2016. Total realized gross losses were $53 for the nine months ended September 30, 2016. There were no total realized gross losses for the nine months ended September 30, 2015.

6. Collaborations

NMP License and Commercialization Agreement

In August 2013, the Company entered into a license and commercialization agreement with Nihon Medi-Physic Co., LTD. (“NMP”) that grants NMP the right to develop and commercialize etarfolatide in Japan for use in connection with vintafolide in Japan. The Company received a $1.0 million non-refundable upfront payment, is eligible for up to $4.5 million based on the successful achievement of regulatory goals for etarfolatide in five different cancer indications and is eligible to receive double-digit percentage royalties on sales of etarfolatide in Japan.

12

For revenue recognition purposes, the Company viewed the agreement with NMP as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company has identified the deliverables related to the collaboration with NMP, which include the license granted to NMP, as well as the obligation to provide preclinical and clinical supply of etarfolatide, to provide rights to NMP if a product is developed that replaces etarfolatide, the obligation for the Company to provide clinical data to NMP during the contract period and the coordination of development and commercialization efforts between the Company for vintafolide and NMP for etarfolatide in Japan. The Company’s deliverables will be accounted for as a single unit of account, therefore the non-refundable upfront payment is being recognized on a straight-line basis over the performance period. This determination was made because the successful development of etarfolatide in Japan requires the ongoing participation by the Company, including the development of the related therapeutic drug, vintafolide. The performance period over which the revenue will be recognized continues from the date of execution of the agreement through the end of 2033, the estimated termination date of the contract which is when the Company’s performance obligations will be completed. Any significant changes in the timing of the performance period could result in a change in the revenue recognition period. The Company had deferred revenue related to the agreement of approximately $0.8 million at September 30, 2016. Subsequent to the inception of the NMP arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered.

The arrangement with NMP includes milestone payments of up to approximately $4.5 million and the milestones are based on the commencement of clinical trials in Japan for specific and non-specific indications and filing for approval in Japan for specific and non-specific indications. The Company evaluated each of these milestone payments and believes that all of the milestones are substantive as there is substantial performance risk that must occur in order for them to be met because the Company must complete additional clinical trials which show a positive outcome or receive approval from a regulatory authority and would be commensurate with the enhancement of value of the underlying intellectual property. To date, the products have not been approved in Japan and no revenue has been recognized related to the regulatory milestones or royalties.

NMP has the right to terminate the collaboration agreement on 90 days notice prior to the first commercial sale in Japan and six months notice after the first commercial sale in Japan. NMP also has the right to terminate the agreement on six months notice if the Company fails to launch vintafolide after receiving regulatory approval in Japan. NMP and the Company each have the right to terminate the agreement due to the material breach or insolvency of the other party. Upon termination of the agreement depending on the circumstances, the parties have varying rights and obligations with respect to licensing and related regulatory materials and data.

7. Stockholders’ Equity (Deficit)

Stock-Based Compensation Plans

The Company has had stock-based compensation plans since 1997. The awards made under the plans adopted in 1997 and 2007 consisted of stock options. The 2010 Equity Incentive Plan (the “2010 Plan”), which is the only plan under which awards may currently be made, authorizes awards in the form of stock options, stock appreciation rights, restricted stock, RSUs, PRSUs and performance units and performance shares. Awards under the 2010 Plan may be made to employees, directors and certain consultants as determined by the compensation committee of the board of directors. There were 9,742,563 and 11,003,563 shares of common stock authorized and reserved under these plans at December 31, 2015 and September 30, 2016, respectively.

Stock Options

Under the various plans, employees have been granted incentive stock options, while directors and consultants have been granted non-qualified options. The plans allow the holder of an option to purchase common stock at the exercise price, which was at or above the fair value of the Company’s common stock on the date of grant.

Generally, options granted under the 1997 and 2007 plans in connection with an employee’s commencement of employment vest over a four-year period with one-half of the shares subject to the grant vesting after two years of employment and remaining options vesting monthly over the remainder of the four-year period. Options granted under the 1997 and 2007 plans for performance or promotions vest monthly over a four-year period. Generally, options granted under the 2010 Plan vest annually over a three-year or four-year period. Unexercised stock options terminate on the tenth

13

anniversary date after the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period. The Company utilizes a Black-Scholes option-pricing model to estimate the value of stock options. The Black-Scholes model allows the use of a range of assumptions related to volatility, risk-free interest rate, employee exercise behavior and dividend yield. Expected volatilities used in the model beginning in 2015 were based on historical volatility of the Company’s stock prices.

Due to insufficient history as a public company, the Company is using the “simplified” method for “plain vanilla” options to estimate the expected term of the stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate assumption is derived from the weighted-average yield of a U.S. Treasury security with the same term as the expected life of the options, and the dividend yield assumption is based on historical experience and the Company’s estimate of future dividend yields.

The weighted-average value of the individual options granted during the three and nine months ended September 30, 2015 and 2016 were determined using the following assumptions:

Three Months Ended September 30,

Nine Months Ended September 30,

2015

2016

2015

2016

Expected volatility

103.0

%

95.9

%

106.5

%

99.0

%

Risk-free interest rate

1.77

%

1.27

%

1.55

%

1.47

%

Weighted-average expected life (in years)

6.3

6.3

6.4

6.6

Dividend yield

0.00

%

0.00

%

0.00

%

0.00

%

14

The Company executed a Separation Agreement and Release of Claims with its former Chief Executive Officer, P. Ron Ellis, in connection with his resignation from the Company in June of 2016. Under this agreement and Mr. Ellis’ original Severance Agreement, the Company incurred additional stock compensation expense of $2.8 million in the nine months ended September 30, 2016 related to the modification of Mr. Ellis’ options and RSUs. The vesting of each stock option and RSU, other than fully vested awards, was modified and the exercise period of each stock option was extended. In determining the additional expense related to the modification of awards, the company revalued the modified options in accordance with ASC 718 using the Black-Scholes model.

The Company’s stock option activity and related information are summarized as follows:

Weighted-Average

Remaining

Weighted-Average

Contractual Term

Aggregate

Options

Exercise Price

(In Years)

Intrinsic Value

Outstanding at January 1, 2016

5,686,815

$

6.87

Granted during period

845,247

3.18

Exercised during period

(48,879)

1.91

Expired during period

(3,836)

7.34

Forfeited during period

—

—

Outstanding at March 31, 2016

6,479,347

$

6.43

6.79

$

308,641

Exercisable at March 31, 2016

4,171,230

$

6.62

5.64

$

308,641

Outstanding at April 1, 2016

6,479,347

6.43

Granted during period

189,900

3.45

Exercised during period

(7,538)

2.10

Expired during period

—

—

Forfeited during period

(105,940)

3.94

Outstanding at June 30, 2016

6,555,769

$

6.38

6.60

$

392,534

Exercisable at June 30, 2016

4,637,674

$

6.65

5.70

$

372,270

Outstanding at July 1, 2016

6,555,769

6.38

Granted during period

22,500

3.21

Exercised during period

(10,471)

1.91

Expired during period

(19,859)

7.48

Forfeited during period

(3,201)

7.44

Outstanding at September 30, 2016

6,544,738

$

6.38

6.37

$

280,274

Exercisable at September 30, 2016

4,646,028

6.68

5.48

280,274

As of September 30, 2016, the total remaining unrecognized compensation cost, net of forfeitures, related to stock options granted was $5.5 million, which is expected to be recognized over a weighted average period of approximately 1.4 years.

Restricted Stock Units

In May 2011, the Company adopted and granted awards under a performance-based RSU program (the “2011 PRSU Program”) under the 2010 Plan. As of September 30, 2016, the performance deadline of May 26, 2016 had passed and all PRSU awards had expired. Each unit represented an amount equal to one share of the Company’s common stock.

The RSUs are service-based awards that will vest and be paid in the form of one share of the Company’s common stock for each RSU, generally in three or four equal annual installments beginning on the first anniversary of the date of grant of the RSU. As of September 30, 2016, the Company had 414,018 RSU awards outstanding. As of September 30, 2016, the total remaining unrecognized compensation cost, net of forfeitures, related to RSUs was $1.4 million, which is expected to be recognized over a weighted average period of approximately 1.5 years.

The following table sets forth the number of RSUs that were granted, vested and forfeited in the periods indicated:

Restricted

Weighted-Average

Stock

Grant

Units

Date Fair Value

Outstanding at January 1, 2016

351,414

$

7.03

Granted during period

222,788

3.18

Vested during period

(104,497)

7.20

Forfeited during period

—

—

Outstanding at March 31, 2016

469,705

$

5.16

Outstanding at April 1, 2016

469,705

$

5.16

Granted during period

28,000

3.47

Vested during period

(60,603)

6.06

Forfeited during period

(20,858)

3.53

Outstanding at June 30, 2016

416,244

$

5.00

Outstanding at July 1, 2016

416,244

$

5.00

Granted during period

3,750

3.21

Vested during period

(5,000)

5.16

Forfeited during period

(976)

5.39

Outstanding at September 30, 2016

414,018

$

4.98

Employee Stock Purchase Plan

At January 1, 2016, 911,725 common shares were available for issuance under the ESPP. Shares may be issued under the ESPP twice a year. In the year ended December 31, 2015, plan participants purchased 74,805 shares of common stock under the ESPP at an average purchase price of $4.08 per share. There were no purchases in the three months ended September 30, 2016. In the nine months ended September 30, 2016, plan participants purchased 44,636 shares of common stock under the ESPP at an average purchase price of $3.09 per share. At September 30, 2016, 867,089 shares were available for issuance under the ESPP.

8. Income Taxes

The Company accounts for income taxes under the liability method in accordance with the provisions of ASC Topic 740,
Income Taxes
. The Company recognizes future tax benefits, such as net operating losses, to the extent those benefits are expected to be realized in future periods. Due to uncertainty surrounding the realization of its deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. The Company experienced a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code in August 2011. As a result, the future use of its net operating losses and credit equivalents is currently limited to approximately $201.9 million for 2016 and $16.8 million for 2017. Any available but unused amounts in 2016 will become available for use in 2017, subject to certain limitations. Utilization of these net operating loss carryforwards would require the Company to generate future taxable income prior to their expiration. Furthermore, the utilization of the net operating loss carryforwards could be limited beyond the Company's generation of taxable income if an additional change in the underlying ownership of the Company's common stock has occurred, resulting in a limitation on the amounts that could be utilized in any given period under Section 382 of the Code.

9. Commitments and Contingencies

On June 24, 2014, a complaint in a securities class action lawsuit was filed against the Company and one of its former officers and directors in the United States District Court for the Southern District of Indiana under the following caption:
Tony Nguyen, on Behalf of Himself and All Others Similarly Situated v. Endocyte, Inc. and P. Ron Ellis
(the “Nguyen Litigation”). On July 13, 2014, a nearly identical complaint in a securities class action lawsuit was filed against the Company and one of its former officers and directors in the United States District Court for the Southern District of Indiana under the following caption:
Vivian Oh Revocable Trust, Individually and on Behalf of All Others
Similarly
Situated v. Endocyte, Inc. and P. Ron Ellis
(the “Oh Litigation”). On September 22, 2014, the court named a lead plaintiff (“Lead Plaintiff”) and consolidated the Nguyen Litigation and the Oh Litigation under the following caption:
Gopichand Vallabhaneni v. Endocyte, Inc. and P. Ron Ellis
(the “Vallabhaneni Litigation”). On November 17, 2014,

16

Lead Plaintiff filed a consolidated amended securities class action complaint (the “Amended Complaint”) against the Company, P. Ron Ellis, Beth Taylor, Michael A. Sherman, John C. Aplin, Philip S. Low, Keith E. Brauer, Ann F. Hanham, Marc Kozin, Peter D. Meldrum, Fred A. Middleton, Lesley Russell (the “Individual Defendants” and collectively with the Company, the “Endocyte Defendants”), and Credit Suisse Securities (USA) LLC and Citigroup Global Markets Inc. (the “Underwriter Defendants”). The court dismissed the lawsuit without prejudice on January 4, 2016, but granted Lead Plaintiff until February 1, 2016 to demonstrate sufficient facts to justify an amended pleading. Lead Plaintiff did not respond, and on February 2, 2016, the court amended the dismissal to be with prejudice and a final order was so entered. Lead Plaintiff appealed the final judgment on March 1, 2016. On March 31, 2016, the appeal was voluntarily dismissed, with prejudice.

On September 23, 2014, a complaint in a shareholder derivative lawsuit was filed against all but one of the Company’s current directors and one of its former directors in the United States District Court for the Southern District of Indiana under the following caption:
William Moore, Derivatively on Behalf of Nominal Defendant Endocyte, Inc. v. John C. Aplin, et al.
(the “Moore Litigation”). The Company was named as a nominal defendant in the case. On October 31, 2014, a complaint in a shareholder derivative lawsuit nearly identical to the Moore Litigation was filed against all but one of the Company’s current directors and one of its former directors in the United States District Court for the Southern District of Indiana under the following caption:
Victor Veloso, Derivatively on Behalf of Endocyte, Inc. v. John C. Aplin, et al.
(the “Veloso Litigation”). The Company was named as a nominal defendant in the case. On December 31, 2014, the court appointed co-lead counsel and consolidated the Moore Litigation with the Veloso Litigation under the following caption:
In re Endocyte, Inc. Derivative Litigation
(the “Endocyte Derivative Litigation”). The lawsuit was voluntarily dismissed without prejudice on April 19, 2016.

On November 6, 2014, a complaint was filed against the Company, one of its current executive officers, one of its former executive officers, Merck and one of Merck’s officers in the Superior Court of Tippecanoe County, Indiana under the following caption:
Mohamad Hage and Jamele Hage v. Endocyte, Inc., P. Ron Ellis, Mike A. Sherman, Eric Rubin and Merck & Co., Inc.
(the “Hage Litigation”). On January 9, 2015, the defendants filed a Motion to Stay the Proceeding or in the Alternative to Stay Discovery (the “Motion to Stay”). A hearing on the Motion to Stay was held on February 19, 2015. On March 20, 2015, the court ruled to stay the case pending final resolution of the Vallabhaneni Litigation. The plaintiffs sought an interlocutory appeal to which the Company opposed. On May 22, 2015, the court denied the interlocutory appeal motion. After a status conference hearing on August 13, 2015, where plaintiffs sought to lift the stay, the court, on September 20, 2015, continued the stay in accordance with its March 20, 2015 ruling. Another status conference hearing was held on March 3, 2016. On July 21, 2016, the lawsuit was voluntarily dismissed, with prejudice.

17

10. Restructuring Costs

The Company terminated the PROCEED trial in May 2014 after the interim futility analysis indicated that vintafolide did not demonstrate efficacy on the pre-specified outcome of progression-free survival for the treatment of platinum-resistant ovarian cancer. As a result, the Company recorded a charge of $4.1 million for remaining expenses of the PROCEED trial, including site close-out expenses, in the year ended December 31, 2014. At September 30, 2016, the Company had a clinical trial accrual balance related to the PROCEED trial termination of $17,800, which is expected to be fully paid in the fourth quarter of 2016.

The following table summarizes the restructuring accruals for the three and nine months ended September 30, 2016:

PROCEED

Trial

Termination

Accrual

Balance at June 30, 2016

$

23,600

Amounts paid in the three months ended September 30, 2016

(5,800)

Balance, September 30, 2016

$

17,800

PROCEED

Trial

Termination

Accrual

Balance, December 31, 2015

$

46,600

Amounts paid in the nine months ended September 30, 2016

(28,800)

Balance, September 30, 2016

$

17,800

18

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q contains certain statements that are forward-looking statements within the meaning of federal securities laws. When used in this report, the words “may,” “will,” “should,” “could,” “would,” “anticipate,” “estimate,” “expect,” “plan,” “believe,” “predict,” “potential,” “project,” “target,” “forecast,” “intend” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include the important risks and uncertainties that may affect our future operations as discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and any other filings made with the Securities and Exchange Commission. Readers of this report are cautioned not to place undue reliance on these forward-looking statements. While we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this report.

Overview

We are a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. We use our proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. Our SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. We are also developing companion imaging agents for each of our SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore most likely to benefit from treatment. This combination of an SMDC with a companion imaging agent is designed to personalize the treatment of patients by delivering effective therapy, selectively to diseased cells, in the patients most likely to benefit. This approach is designed to yield multiple drug candidates that could treat disease through the following multiple mechanisms: by direct and targeted killing of cells, by killing tumor-associated macrophages which otherwise inhibit the immune system, or by activating the immune system directly by combining SMDCs with checkpoint inhibitors or our chimeric antigen receptor (CAR) T-cell approach.

We had two wholly-owned subsidiaries, Endocyte Europe B.V. and Endocyte Europe GmbH, which were formed to assist with pre-commercial activity that subsequently ceased. We dissolved Endocyte Europe GmbH in the fourth quarter of 2015 and dissolved Endocyte Europe B.V. in the first quarter of 2016.

For the nine months ended September 30, 2016, we had a net loss of $32.8 million compared to a net loss of $31.5 million for the nine months ended September 30, 2015. We had a retained deficit of $242.6 million at September 30, 2016. We expect to continue to incur significant operating losses for the next several years as we pursue the advancement of our SMDCs and companion imaging agents through the research, development, regulatory and commercialization processes. Our operating costs were higher for the nine months ended September 30, 2016 compared to the nine months ended September 30, 2015 primarily due to an increase in compensation expense related to the resignation of our former Chief Executive Officer, P. Ron Ellis, in June of 2016, which was partially offset by a decrease in expenses related to the TARGET trial, which is now complete, and decreases in other compensation expense and legal and professional fees.

We completed the close-out activities for the TARGET trial, a randomized phase 2b trial of vintafolide for use in non-small cell lung cancer, or NSCLC, during 2015 and announced the final results during the third quarter of 2015. We presented the final overall survival, or OS, data at the World Lung Cancer Conference in September 2015. At that meeting, we reported that vintafolide plus docetaxel improved median OS by 2.7 months in NSCLC regardless of histology (Median OS 11.5 vs. 8.8 months, OS HR=0.86, 95% CI [0.58, 1.26]). In the predefined subset analysis of patients with adenocarcinoma, which expresses higher levels of folate receptor, or FR, vintafolide plus docetaxel improved median OS by 5.9 months (12.5 vs. 6.6 months, HR=0.72, 95% CI [0.44, 1.16]). OS for vintafolide as single agent was similar to docetaxel (OS 8.4 vs. 8.8 months, HR=1.02, 95% CI [0.70, 1.50]). The safety profiles of vintafolide alone and docetaxel alone were consistent with previous observations, but the combination of vintafolide and docetaxel resulted in higher rates of hematologic and peripheral neuropathy adverse events. Our current focus is on the development of our second generation folate targeted agent, EC1456, in second-line NSCLC and our first non-folate SMDC, EC1169, in advanced metastatic castration-resistant prostate cancer, or mCRPC, as discussed below.

19

Research and development expenses relating to EC1456, our second generation SMDC, were higher for the nine months ended September 30, 2016 compared to the nine months ended September 30, 2015, as we continued to enroll patients in a phase 1 dose escalation trial for the treatment of advanced solid tumors with EC1456. The most recent cohort of EC1456 patients have been treated with a dose that exceeds the dose of vintafolide delivered in trials to date. Patients are scanned with etarfolatide, but we are not limiting enrollment based on the results of the scan. We presented data at the European Society for Medical Oncology, or ESMO, 2016 Congress in October. In spite of the inclusion of patients in the dose escalation phase who were not selected as positive for the targeted FR, most patients demonstrated stable disease as best response and several patients demonstrated a reduction in target tumor volume. As the maximum clinical dose of 6.0 mg/m
2
has been determined for the biweekly dosing schedule, we opened the expansion phase of the trial in the third quarter of 2016 to evaluate EC1456 in up to 40 patients with NSCLC known to express the FR. Once the maximum clinical dose is determined for a once weekly dosing schedule, we plan to similarly expand the trial to evaluate EC1456 at this dose as well. We will evaluate single agent tumor response, which will inform and may trigger additional work in combination therapies and indications such as triple-negative breast cancer, ovarian cancer, and endometrial cancer.

Research and development expenses relating to EC1169, our first non-folate SMDC, increased in the nine months ended September 30, 2016 compared to the nine months ended September 30, 2015, as we continued to enroll patients in a phase 1 dose escalation trial in advanced prostate cancer for EC1169 and scan patients with our companion imaging agent, EC0652. Enrollment of the dose escalation trial was completed in October of 2016. Patients were scanned prior to therapy to identify the presence of prostate-specific membrane antigen, or PSMA, but we did not limit enrollment based on the results of the scan. To date, EC0652 has shown the presence of PSMA in at least one lesion in all prostate cancer patients scanned. We presented data at ESMO 2016 Congress in October. The data showed that total target tumor burden reduction was observed in 4 of the 6 patients with measurable soft tissue disease treated at doses of 3.8 mg/m
2
and higher. One of these patients demonstrated the first confirmed radiologic partial tumor response, or PR, as measured by Response Evaluation Criteria in Solid Tumors, or RECIST, 1.1 criteria. Two patients also demonstrated confirmed prostate specific antigen reductions of greater than 50%, one of whom went on to demonstrate the PR. After observing toxicity at 8.5 mg/m
2
, we have confirmed 6.5 mg/m
2
as the maximum clinical dose and are now expanding the trial to evaluate EC1169 in up to 100 taxane-exposed and taxane-naïve mCRPC patients.

As of September 30, 2016, our cash, cash equivalents and investments were $146.7 million. We believe that our current cash balance will be sufficient to fund our current operating plan, including the advancement of our pipeline.

Critical Accounting Policies

Our significant accounting policies are described in more detail in our 2015 Annual Report on Form 10-K. There were no changes in the three and nine months ended September 30, 2016 to the application of the accounting policies that are critical to the judgments and estimates used in the preparation of our condensed consolidated financial statements.

20

Results of Operations

Comparison of Three Months Ended September 30, 2015 to Three Months Ended September 30, 2016